Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nolpitantium Besylate in Mild to Moderate Ulcerative Colitis
NCT00232258Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of nolpitantium in ulcerative colitis (UC) (3 arms), sponsored by Sanofi. Primary endpoint: Clinical remission defined as a clinical Mayo subscore </= 1 at 8 weeks. Started Apr 2005; status: completed.
02
Drugs
nolpitantium
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00232258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232258.